Published in Infect Immun on February 01, 2003
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A (2004) 3.52
Genotyping Mycobacterium ulcerans and Mycobacterium marinum by using mycobacterial interspersed repetitive units. J Bacteriol (2005) 2.06
First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis (2008) 1.93
Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F. Infect Immun (2006) 1.91
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 1.77
A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin. Infect Immun (2005) 1.73
Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun (2005) 1.59
On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics (2012) 1.58
Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. J Bacteriol (2005) 1.55
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun (2006) 1.45
Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun (2007) 1.40
HUMAN MICROBIOTA. Small molecules from the human microbiota. Science (2015) 1.34
Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep (2008) 1.32
Subtractive hybridization reveals a type I polyketide synthase locus specific to Mycobacterium ulcerans. J Bacteriol (2003) 1.15
The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol (2006) 1.13
Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue. PLoS Negl Trop Dis (2010) 1.11
Mycobacterium ulcerans disease, Peru. Emerg Infect Dis (2008) 1.07
Interaction of Mycobacterium ulcerans with mosquito species: implications for transmission and trophic relationships. Appl Environ Microbiol (2010) 1.05
Deciphering the genetic basis for polyketide variation among mycobacteria producing mycolactones. BMC Genomics (2008) 1.04
A novel mycolactone toxin obtained by biosynthetic engineering. Chembiochem (2007) 1.02
Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer. Am J Pathol (2006) 1.02
Large sequence polymorphisms unveil the phylogenetic relationship of environmental and pathogenic mycobacteria related to Mycobacterium ulcerans. Appl Environ Microbiol (2009) 1.00
Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun (2010) 1.00
Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis (2013) 0.98
Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination. PLoS One (2012) 0.92
Analysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone. Infect Immun (2004) 0.91
Mycobacterium ulcerans and other mycolactone-producing mycobacteria should be considered a single species. PLoS Negl Trop Dis (2010) 0.91
Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl Trop Dis (2013) 0.90
Total Synthesis of Mycolactones A and B. Tetrahedron (2007) 0.88
Chemistry of mycolactones, the causative toxins of Buruli ulcer. Proc Natl Acad Sci U S A (2011) 0.87
Proteomic analysis of the action of the Mycobacterium ulcerans toxin mycolactone: targeting host cells cytoskeleton and collagen. PLoS Negl Trop Dis (2014) 0.86
Differential gene repertoire in Mycobacterium ulcerans identifies candidate genes for patho-adaptation. PLoS Negl Trop Dis (2008) 0.85
Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity. PLoS One (2010) 0.85
Systemic and local interferon-gamma production following Mycobacterium ulcerans infection. Clin Exp Immunol (2007) 0.84
Lack of insertional-deletional polymorphism in a collection of Mycobacterium ulcerans isolates from Ghanaian Buruli ulcer patients. J Clin Microbiol (2009) 0.83
Structure-activity relationship studies on the macrolide exotoxin mycolactone of Mycobacterium ulcerans. PLoS Negl Trop Dis (2013) 0.82
Synthesis and structure of mycolactone E isolated from frog mycobacterium. Org Lett (2008) 0.81
The cell wall-associated mycolactone polyketide synthases are necessary but not sufficient for mycolactone biosynthesis. PLoS One (2013) 0.81
Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. Clin Exp Immunol (2009) 0.81
Mycobacterium liflandii outbreak in a research colony of Xenopus (Silurana) tropicalis frogs. Vet Pathol (2010) 0.81
Mycobacterium ulcerans causes minimal pathogenesis and colonization in medaka (Oryzias latipes): an experimental fish model of disease transmission. Microbes Infect (2012) 0.80
Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. Cell Microbiol (2016) 0.79
Synthesis and structure assignment of the minor metabolite arising from the frog pathogen Mycobacterium liflandii. Tetrahedron Lett (2010) 0.79
Antibody-Mediated Neutralization of the Exotoxin Mycolactone, the Main Virulence Factor Produced by Mycobacterium ulcerans. PLoS Negl Trop Dis (2016) 0.77
Photodegradation of the Mycobacterium ulcerans toxin, mycolactones: considerations for handling and storage. PLoS One (2012) 0.77
Highly stereoselective total synthesis of fully hydroxy-protected mycolactones A and B and their stereoisomerization upon deprotection. Chemistry (2011) 0.77
Scalable and efficient synthesis of the mycolactone core. Tetrahedron (2010) 0.77
Natural products as mediators of disease. Nat Prod Rep (2016) 0.75
Heterogeneous Family of Cyclomodulins: Smart Weapons That Allow Bacteria to Hijack the Eukaryotic Cell Cycle and Promote Infections. Front Cell Infect Microbiol (2017) 0.75
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science (1999) 6.37
Mycobacterium ulcerans infection. Lancet (1999) 4.52
A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun (2000) 3.27
Polyketide synthesis: prospects for hybrid antibiotics. Annu Rev Microbiol (1993) 3.12
A gene cluster for macrolide antibiotic biosynthesis in Streptomyces venezuelae: architecture of metabolic diversity. Proc Natl Acad Sci U S A (1998) 3.01
Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect Immun (1998) 1.93
Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J Clin Pathol (1993) 1.91
Mycobacterium ulcerans infection. Clinical and bacteriological study of the first cases recognized in South East Asia. Br J Dermatol (1966) 1.77
Mycobacterium ulcerans infection (with comments on pathogenesis). Int J Lepr (1966) 1.68
Manipulation of Modular Polyketide Synthases. Chem Rev (1997) 1.64
Complete structure of the mycolactones. J Am Chem Soc (2001) 1.27
Stereochemistry of the core structure of the mycolactones. J Am Chem Soc (2001) 1.25
The phenolic mycoside of Mycobacterium ulcerans: structure and taxonomic implications. J Gen Microbiol (1992) 1.22
First reported case of Mycobacterium ulcerans infection in a patient from China. Trans R Soc Trop Med Hyg (2000) 1.19
MYCOBACTERIAL SKIN ULCERS IN UGANDA: HISTOPATHOLOGICAL AND EXPERIMENTAL ASPECTS. J Pathol Bacteriol (1964) 1.14
Suspension cultivation of Mycobacterium ulcerans for the production of mycolactones. FEMS Microbiol Lett (2001) 1.13
Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol (2006) 11.86
Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41
Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet (2006) 4.73
Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 4.10
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A (2004) 3.52
Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis (2004) 3.08
Molecular evidence to support a proposal to reserve the designation Mycobacterium avium subsp. avium for bird-type isolates and 'M. avium subsp. hominissuis' for the human/porcine type of M. avium. Int J Syst Evol Microbiol (2002) 3.02
Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect Dis (2006) 2.73
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol (2011) 2.68
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol (2012) 2.40
Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother (2005) 2.35
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg (2004) 2.29
Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res (2006) 2.15
Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor. J Bacteriol (2006) 2.10
Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin. Trop Med Int Health (2003) 2.07
Genotyping Mycobacterium ulcerans and Mycobacterium marinum by using mycobacterial interspersed repetitive units. J Bacteriol (2005) 2.06
Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. J Clin Microbiol (2004) 2.06
Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother (2003) 1.93
Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F. Infect Immun (2006) 1.91
Risk factors for buruli ulcer: a case control study in Cameroon. PLoS Negl Trop Dis (2007) 1.90
Buruli ulcer (Mycobacterium ulcerans infection). Trans R Soc Trop Med Hyg (2008) 1.88
Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS One (2009) 1.87
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother (2009) 1.82
Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother (2006) 1.80
Mycobacteria in drinking water distribution systems: ecology and significance for human health. FEMS Microbiol Rev (2005) 1.79
Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium. J Clin Microbiol (2007) 1.79
Multilocus variable-number tandem repeat typing of Mycobacterium ulcerans. J Clin Microbiol (2005) 1.77
A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin. Infect Immun (2005) 1.73
The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother (2008) 1.71
High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother (2009) 1.69
Buruli ulcer recurrence, Benin. Emerg Infect Dis (2005) 1.69
One-tube cell lysis and DNA extraction procedure for PCR-based detection of Mycobacterium ulcerans in aquatic insects, molluscs and fish. J Med Microbiol (2004) 1.59
Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun (2005) 1.59
On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics (2012) 1.58
A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother (2008) 1.58
Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol (2004) 1.57
Acyl-phosphates initiate membrane phospholipid synthesis in Gram-positive pathogens. Mol Cell (2006) 1.56
Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. J Med Chem (2004) 1.55
Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother (2005) 1.53
Buruli ulcer distribution in Benin. Emerg Infect Dis (2005) 1.52
Rapid alternative methods for detection of rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother (2004) 1.51
Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis (2010) 1.48
Methods for acquisition and assignment of multidimensional high-resolution magic angle spinning NMR of whole cell bacteria. Anal Chem (2005) 1.46
Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol (2006) 1.45
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun (2006) 1.45
Genetic diversity in Mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol (2006) 1.44
Defining "rural" for veterans' health care planning. J Rural Health (2010) 1.43
Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. Am J Trop Med Hyg (2006) 1.42
Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin (2011) 1.37
Chemical knockout of pantothenate kinase reveals the metabolic and genetic program responsible for hepatic coenzyme A homeostasis. Chem Biol (2007) 1.35
Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol (2009) 1.34
Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay. J Clin Microbiol (2006) 1.34
Acyl carrier protein is a cellular target for the antibacterial action of the pantothenamide class of pantothenate antimetabolites. J Biol Chem (2004) 1.33
Novel acyl phosphate mimics that target PlsY, an essential acyltransferase in gram-positive bacteria. ChemMedChem (2008) 1.31
Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis (2009) 1.27
Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg Med Chem Lett (2003) 1.25
Buruli ulcer surveillance, Benin, 2003-2005. Emerg Infect Dis (2007) 1.20
Validation of molecular docking programs for virtual screening against dihydropteroate synthase. J Chem Inf Model (2009) 1.19
Structure-activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors. Bioorg Med Chem (2005) 1.19
PCR amplification with primers based on IS2404 and GC-rich repeated sequence reveals polymorphism in Mycobacterium ulcerans. J Clin Microbiol (2005) 1.19
Newly developed primers for the detection of Mycobacterium avium subspecies paratuberculosis. Vet Microbiol (2004) 1.19
Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol (2004) 1.18
A pantothenate kinase from Staphylococcus aureus refractory to feedback regulation by coenzyme A. J Biol Chem (2004) 1.17
Family relationship, water contact and occurrence of Buruli ulcer in Benin. PLoS Negl Trop Dis (2010) 1.16
A comparison of DNA extraction procedures for the detection of Mycobacterium ulcerans, the causative agent of Buruli ulcer, in clinical and environmental specimens. J Microbiol Methods (2008) 1.16
Buruli ulcer: a systemic disease. Clin Infect Dis (2003) 1.16
Ongoing genome reduction in Mycobacterium ulcerans. Emerg Infect Dis (2007) 1.16
Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents. J Med Chem (2005) 1.15
N-substituted 3-acetyltetramic acid derivatives as antibacterial agents. J Med Chem (2008) 1.14
Catalysis and sulfa drug resistance in dihydropteroate synthase. Science (2012) 1.14
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
A statistical framework to evaluate virtual screening. BMC Bioinformatics (2009) 1.14
Heterogeneity among Mycobacterium ulcerans isolates from Africa. Emerg Infect Dis (2006) 1.13
Comparative nucleotide sequence analysis of polymorphic variable-number tandem-repeat Loci in Mycobacterium ulcerans. J Clin Microbiol (2005) 1.13
Crystal structure of 7,8-dihydropteroate synthase from Bacillus anthracis: mechanism and novel inhibitor design. Structure (2004) 1.13
Terrestrial small mammals as reservoirs of Mycobacterium ulcerans in benin. Appl Environ Microbiol (2010) 1.13
Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb Pathog (2003) 1.13
Biomechanical evaluation of an injectable calcium phosphate cement for vertebroplasty. Spine (Phila Pa 1976) (2002) 1.12
A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother (2006) 1.11
Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorg Med Chem Lett (2007) 1.11
Aquatic insects and Mycobacterium ulcerans: an association relevant to Buruli ulcer control? PLoS Med (2007) 1.11
Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue. PLoS Negl Trop Dis (2010) 1.11
Persistent association of Mycobacterium ulcerans with West African predaceous insects of the family belostomatidae. Appl Environ Microbiol (2008) 1.11
Continuous up-regulation of heat shock proteins in larvae, but not adults, of a polar insect. Proc Natl Acad Sci U S A (2006) 1.11
Dehydration-induced cross tolerance of Belgica antarctica larvae to cold and heat is facilitated by trehalose accumulation. Comp Biochem Physiol A Mol Integr Physiol (2008) 1.10
Buruli ulcer: a review of in vitro tests to screen natural products for activity against Mycobacterium ulcerans. Planta Med (2011) 1.10
Structural characterization of the Mycobacterium tuberculosis biotin biosynthesis enzymes 7,8-diaminopelargonic acid synthase and dethiobiotin synthetase . Biochemistry (2010) 1.09
Nitrofurans as novel anti-tuberculosis agents: identification, development and evaluation. Curr Top Med Chem (2007) 1.09
Rapid cold-hardening protects Drosophila melanogaster from cold-induced apoptosis. Apoptosis (2007) 1.08
Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS (2008) 1.08
African 2, a clonal complex of Mycobacterium bovis epidemiologically important in East Africa. J Bacteriol (2010) 1.08
Cryoprotection by urea in a terrestrially hibernating frog. J Exp Biol (2005) 1.08
VNTR analysis differentiates Mycobacterium ulcerans and IS2404 positive mycobacteria. Syst Appl Microbiol (2007) 1.07
Pantothenamides are potent, on-target inhibitors of Plasmodium falciparum growth when serum pantetheinase is inactivated. PLoS One (2013) 1.07
Environmental and health-related risk factors for Mycobacterium ulcerans disease (Buruli ulcer) in Benin. Am J Trop Med Hyg (2007) 1.07
The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg Med Chem (2011) 1.07
Mycobacterium ulcerans disease, Peru. Emerg Infect Dis (2008) 1.07